Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer
JHL Biotech received a positive Scientific Advice from the Committee for Medicinal Products for Human Use of the European Medicines Agency related to the EU approval pathway for its proposed bevacizumab biosimilar JHL1149 to treat patients with non-small cell lung cancer.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
Novartis launched its Galaxies of Hope app, a unique digital experience created to support the neuroendocrine tumor community.
Colon cancer patients who drink one or more servings of artificially sweetened beverages a day have roughly half the risk of their cancer recurring compared to those who drink few or none of these beverages, a U.S. study suggests.
The U.S. Food and Drug Administration approved the first non-radioactive, dual-tracer for sentinel lymph node biopsy.
The European Commission approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
The FDA approved Azedra injection for intravenous use for treating patients age 12 and older with rare tumors of the adrenal gland that cannot be surgically removed, have spread beyond the original tumor site and require systemic anticancer therapy.
BioLineRx Ltd. announced the expansion of its immuno-oncology collaboration with Merck & Co. Inc. for the support of a Phase 2a program investigating BioLineRx’s BL-8040 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) in patients with metastatic pancreatic cancer.
Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.
AstraZeneca’s new drugs performed strongly in second-quarter 2018, offering a glimpse of better times ahead as the company struggles with falling sales of the cholesterol fighter Crestor due to generic competition.
Takeda Pharmaceutical’s Alunbrig (brigatinib) hit its Phase III primary endpoints of statistically significant improvement in progression-free survival compared to Pfizer’s Xalkori (crizotinib) in a subset of lung cancer patients following the first pre-specified interim analysis.
Celgene Reports Promising Data For Revlimid-Rituximab Combination For Relapsed/Refractory Indolent Lymphoma
Celgene Corporation announced results from a phase III, randomized, double-blind, international clinical study AUGMENT showing that Revlimid (lenalidomide) plus rituximab (R2) achieved a highly statistically significant improvement in the primary endpoint of progression-free survival compared to rituximab plus placebo, in the final PFS analysis.
BeiGene Ltd. announced that the commercial-stage biopharmaceutical company’s investigational BTK inhibitor zanubrutinib was granted Fast Track designation by the U.S. FDA for the treatment of patients with Waldenström macroglobulinemia.
Mersana Therapeutics said on Thursday an early-stage trial testing the company’s lead cancer drug was put on partial hold by the U.S. FDA after a patient’s death was possibly linked to the treatment.
Novartis is halting planned price increases on the Swiss pharma giant’s medications after President Donald Trump took Pfizer to task over price hikes, with Pfizer subsequently agreeing to roll back the company’s price increases.
In April 2018, Bay Area biotech Revolution Medicines completed its pivot from a company focused on antifungal treatments to an oncology business. Revolution’s shift paid off with a development deal worth up to $500 million with Sanofi.
J&J topped analysts’ estimates for Q2 2018 profit and revenue with strong demand for the cancer drugs Zytiga and Darzalex.
Johnson & Johnson vowed to appeal a $4.7 billion verdict awarded to 22 women who claim asbestos-contaminated talc in the company’s products gave them ovarian cancer by arguing the plaintiffs’ science was flawed and the case should not have been heard in Missouri.
U.S. FDA Approves Xtandi for Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer
Astellas Pharma Inc. and Pfizer Inc. announced the U.S. FDA approved a supplemental New Drug Application for Xtandi (enzalutamide), following FDA Priority Review designation.